The Renin-angiotensin System Biomolecular Cascade: a 2022 Update of Newer Insights and Concepts

Overview

Journal Kidney Int Suppl (2011)

Publisher Elsevier

Specialty Nephrology

Date 2022 May 9

PMID 35529089

Authors

Carlos M Ferrario

Leanne Groban

Hao Wang

Xuming Sun

Jessica L VonCannon

Kendra N Wright

Sarfaraz Ahmad

Affiliations

Soon will be listed here.

Abstract

A large body of evidence implicates the renin-angiotensin system in the pathogenesis of cardiovascular disease. However, not everyone understands that the magnitude of the risk reduction achieved in clinical trials with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers is only a fraction of the residual risk for cardiovascular events and death. This paper addresses limitations of current therapeutic approaches based on renin-angiotensin system blockade for hypertension and cardiovascular disease by illustrating the complex biochemical physiology and mechanism of classical and alternate angiotensin peptide formation. Emerging evidence of alternate mechanisms that bypass both renin and angiotensin-converting enzyme to produce the angiotensins in tissues and cells is not currently universally recognized. Currently available treatment would benefit from further insights to help fully meet the aims of patient care, and the challenge is to delve more deeply into the renin-angiotensin system cascade, with the aim of enhancing therapeutics for renin-angiotensin system inhibition. This article provides a reappraisal of the renin-angiotensin-aldosterone cascade, highlighting newly elucidated intermediary components and interplay, and their consequent implications and relevance for understanding the long-term contribution of angiotensin II in cardiovascular diseases and their therapy.

Citing Articles

Renin-Angiotensin-Aldosterone System Profiling in Horses Before and After Exercise.

Holbrook T, Hernandez J, McCarrel T, Lester G, Sleeper M, Domenig O J Vet Intern Med. 2025; 39(2):e70036.

PMID: 40048547 PMC: 11884522. DOI: 10.1111/jvim.70036.

Angiotensin II Promotes Osteocyte RANKL Expression via AT1R Activation.

Ren J, Marahleh A, Ma J, Ohori F, Noguchi T, Fan Z Biomedicines. 2025; 13(2).

PMID: 40002839 PMC: 11853621. DOI: 10.3390/biomedicines13020426.

Differing sensitivities to angiotensin converting enzyme inhibition of kidney disease mediated by APOL1 high-risk variants G1 and G2.

Sula Karreci E, Jacas S, Donovan O, Pintye D, Wiley N, Zsengeller Z Kidney Int. 2024; 106(6):1072-1085.

PMID: 39181397 PMC: 11585418. DOI: 10.1016/j.kint.2024.07.026.

What Are the Key Factors for the Detection of Peptides Using Mass Spectrometry on Boron-Doped Diamond Surfaces?.

Aguedo J, Vojs M, Vrska M, Nemcovic M, Pakanova Z, Dragounova K Nanomaterials (Basel). 2024; 14(15).

PMID: 39120346 PMC: 11314266. DOI: 10.3390/nano14151241.

Multi-omics Investigations in Endocrine Systems and Their Clinical Implications.

Peliciari-Garcia R, de Barros C, Secio-Silva A, de Barros Peruchetti D, Romano R, Bargi-Souza P Adv Exp Med Biol. 2024; 1443:187-209.

PMID: 38409422 DOI: 10.1007/978-3-031-50624-6_10.

References

Bakris G, Oparil S, Purkayastha D, Yadao A, Alessi T, Sowers J . Randomized study of antihypertensive efficacy and safety of combination aliskiren/valsartan vs valsartan monotherapy in hypertensive participants with type 2 diabetes mellitus. J Clin Hypertens (Greenwich). 2013; 15(2):92-100. PMC: 8108251. DOI: 10.1111/jch.12032. View

Ferrario C, Ahmad S, Groban L . Twenty years of progress in angiotensin converting enzyme 2 and its link to SARS-CoV-2 disease. Clin Sci (Lond). 2020; 134(19):2645-2664. PMC: 9055624. DOI: 10.1042/CS20200901. View

Boucher R, Demassieux S, Garcia R, Genest J . Tonin, angiotensin II system. A review. Circ Res. 1977; 41(4 Suppl 2):26-9. DOI: 10.1161/01.res.41.4.26. View

Wu C, Wang Y, Ma M, Mullick A, Crooke R, Graham M . Antisense oligonucleotides targeting angiotensinogen: insights from animal studies. Biosci Rep. 2018; 39(1). PMC: 6328882. DOI: 10.1042/BSR20180201. View

Zanchetti A, Hansson L, Dahlof B, Elmfeldt D, Kjeldsen S, Kolloch R . Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study. HOT Study Group. J Hypertens. 2001; 19(6):1149-59. DOI: 10.1097/00004872-200106000-00021. View

Re R . Role of intracellular angiotensin II. Am J Physiol Heart Circ Physiol. 2018; 314(4):H766-H771. DOI: 10.1152/ajpheart.00632.2017. View

Ferrario C, Groban L, Wang H, Ahmad S . Letter to the Editor: Brain renin-angiotensin system and liver-directed siRNA targeted to angiotensinogen. Clin Sci (Lond). 2021; 135(7):907-910. DOI: 10.1042/CS20210163. View

Phillips M, Kimura B . Antisense therapeutics for hypertension: targeting the renin-angiotensin system. Methods Mol Med. 2004; 106:51-68. View

Ansary T, Urushihara M, Fujisawa Y, Nagata S, Urata H, Nakano D . Effects of the selective chymase inhibitor TEI-F00806 on the intrarenal renin-angiotensin system in salt-treated angiotensin I-infused hypertensive mice. Exp Physiol. 2018; 103(11):1524-1531. DOI: 10.1113/EP087209. View

10.

Lu H, Cassis L, Vander Kooi C, Daugherty A . Corrigendum: Structure and functions of angiotensinogen. Hypertens Res. 2016; 39(11):827. PMC: 7608451. DOI: 10.1038/hr.2016.106. View

11.

Ahmad S, Varagic J, Groban L, DellItalia L, Nagata S, Kon N . Angiotensin-(1-12): a chymase-mediated cellular angiotensin II substrate. Curr Hypertens Rep. 2014; 16(5):429. PMC: 4007169. DOI: 10.1007/s11906-014-0429-9. View

12.

Gordon D, Sachin I, Dodd V . Heterogeneity of renin substrate in human plasma: effect of pregnancy and oral contraceptives. Proc Soc Exp Biol Med. 1976; 153(2):314-8. DOI: 10.3181/00379727-153-39536. View

13.

Lautner R, Villela D, Fraga-Silva R, Silva N, Verano-Braga T, Costa-Fraga F . Discovery and characterization of alamandine: a novel component of the renin-angiotensin system. Circ Res. 2013; 112(8):1104-11. DOI: 10.1161/CIRCRESAHA.113.301077. View

14.

Haber E . Immunologic approaches to the inhibition of renin and the adrenergic system. Fed Proc. 1983; 42(10):2661-6. View

15.

Uijl E, Mirabito Colafella K, Sun Y, Ren L, Van Veghel R, Garrelds I . Strong and Sustained Antihypertensive Effect of Small Interfering RNA Targeting Liver Angiotensinogen. Hypertension. 2019; 73(6):1249-1257. DOI: 10.1161/HYPERTENSIONAHA.119.12703. View

16.

Yamashita T, Ahmad S, Wright K, Roberts D, VonCannon J, Wang H . Noncanonical Mechanisms for Direct Bone Marrow Generating Ang II (Angiotensin II) Predominate in CD68 Positive Myeloid Lineage Cells. Hypertension. 2019; 75(2):500-509. PMC: 6949383. DOI: 10.1161/HYPERTENSIONAHA.119.13754. View

17.

Ferrario C . Angiotensin-converting enzyme 2 and angiotensin-(1-7): an evolving story in cardiovascular regulation. Hypertension. 2005; 47(3):515-21. DOI: 10.1161/01.HYP.0000196268.08909.fb. View

18.

Dupre E, Danis C, Arrial A, Hanoulle X, Homa M, Cantrelle F . Single Domain Antibody Fragments as New Tools for the Detection of Neuronal Tau Protein in Cells and in Mice Studies. ACS Chem Neurosci. 2019; 10(9):3997-4006. DOI: 10.1021/acschemneuro.9b00217. View

19.

Uijl E, Ren L, Mirabito Colafella K, Van Veghel R, Garrelds I, Domenig O . No evidence for brain renin-angiotensin system activation during DOCA-salt hypertension. Clin Sci (Lond). 2021; 135(2):259-274. DOI: 10.1042/CS20201239. View

20.

Batlle D, Wysocki J, Satchell K . Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy?. Clin Sci (Lond). 2020; 134(5):543-545. DOI: 10.1042/CS20200163. View